PharmaMar deal adds late-stage asset to Jazz’s growing cancer pipeline

Jazz’s deal to gain exclusive, U.S. rights to PharmaMar’s Zepsyre marks the company’s third cancer partnership of the year, adding a late-stage asset in small cell lung cancer as it continues to expand its pipeline beyond its flagship narcolepsy programs.

PharmaMar S.A. (Madrid:PHM) will receive $200 million up front and up to $250 million upon FDA approval of Zepsyre lurbinectedin. The Spanish company is also eligible to receive up to $550 million in commercial milestones from Jazz Pharmaceuticals plc (NASDAQ:JAZZ), plus high-teen to 30% tiered royalties. ...